Digest Network Come funziona
Network
/
Società
En
Non verificato

Ensem Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
01/10/2025
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Ensem Therapeutics Announces ETX-636 Granted Fast Track Designation by the FDA for Advanced Breast Cancer
Fonte
Ensem Therapeutics, Inc.
Emittente
Business Wire
1.00
0
01/07/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Ensem Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ETX-636, a Potential Best-In-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader
Fonte
Ensem Therapeutics, Inc.
Emittente
Business Wire
1.00
0
22/04/2025
Industria
Biotecnologia
Tecnica
Igiene alimentare
Salute
Farmaceutica
Oncologia
Scienza
Medicina - Varie
Ensem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636
Fonte
Ensem Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/01/2025
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Ensem Therapeutics Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Fonte
Ensem Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/12/2024
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader at San Antonio Breast Cancer Symposium
Fonte
Ensem Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/12/2024
Eventi
Industria
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Oral CDK2 Inhibitor at San Antonio Breast Cancer Symposium
Fonte
Ensem Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0